Godd news for ILUVIEN. "We began generating revenue from ILUVIEN in the second quarter of 2013 in Germany and the United Kingdom.....
..and continue to make progress in gaining market access in Germany, the United Kingdom and France," said Dan Myers, Alimera's president and chief executive officer. "The initial response has been very positive among early adopting physicians as well as patients, with some of the patients receiving an implant in both eyes."
The approval in October of ILUVIEN will be almost a formality. The proof will be even stronger at the end of September of the efficacy and benefit of ILUVIEN for patients.
After approval we will receive a $ 25 Million dollars minus some $7-7 Millions for various expenses of commecialisation.